Cargando…

Identification of a novel fusion Iduronidase with improved activity in the cardiovascular system

BACKGROUND: Lysosomal diseases are a group of over 70 rare genetic conditions in which a protein deficiency (most often an enzyme deficiency) leads to multi-system disease. Current therapies for lysosomal diseases are limited in their ability to treat certain tissues that are major contributors to m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Sarah, Przybilla, Michael J., Whitley, Chester B., Ou, Li, Al-Kofahi, Mahmoud, Jarnes, Jeanine R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489536/ https://www.ncbi.nlm.nih.gov/pubmed/36159322 http://dx.doi.org/10.1016/j.ymgmr.2022.100917

Ejemplares similares

Genotype-phenotype correlation of gangliosidosis mutations using in silico tools and homology modeling
por: Ou, Li, et al.
Publicado: (2019)

Chitotriosidase as a biomarker for gangliosidoses
por: Kim, Sarah, et al.
Publicado: (2021)

Examination of a blood-brain barrier targeting β-galactosidase-monoclonal antibody fusion protein in a murine model of GM1-gangliosidosis
por: Przybilla, Michael J., et al.
Publicado: (2021)

The juvenile gangliosidoses: A timeline of clinical change
por: King, Kelly E., et al.
Publicado: (2020)

Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report(,)
por: Kim, Sarah, et al.
Publicado: (2017)

Hypothyroidism in late-onset Pompe disease
por: Schneider, Joseph, et al.
Publicado: (2016)

Elements of lentiviral vector design toward gene therapy for treating mucopolysaccharidosis I
por: Ou, Li, et al.
Publicado: (2016)

Phenotype prediction for mucopolysaccharidosis type I by in silico analysis
por: Ou, Li, et al.
Publicado: (2017)

New Irreversible α‐l‐Iduronidase Inhibitors and Activity‐Based Probes
por: Artola, Marta, et al.
Publicado: (2018)

Physiologically‐Based Pharmacokinetic Model Development, Validation, and Application for Prediction of Eliglustat Drug–Drug Interactions
por: Sahasrabudhe, Siddhee A., et al.
Publicado: (2022)

α-L-iduronidase therapy for mucopolysaccharidosis type I
por: Tolar, Jakub, et al.
Publicado: (2008)

Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: Volumetric quantitative MRI study
por: Nestrasil, Igor, et al.
Publicado: (2017)

Long-term cognitive and somatic outcomes of enzyme replacement therapy in untransplanted Hurler syndrome
por: Eisengart, Julie B., et al.
Publicado: (2017)

Insights into Mucopolysaccharidosis I from the structure and action of α-L-Iduronidase
por: Bie, Haiying, et al.
Publicado: (2013)

Mucopolysaccharidosis type I: molecular characteristics of two novel alpha-L-iduronidase mutations in Tunisian patients
por: Chkioua, Latifa, et al.
Publicado: (2011)

Three novel α-L-iduronidase mutations in 10 unrelated Chinese mucopolysaccharidosis type I families
por: Sun, Luning, et al.
Publicado: (2011)

A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases
por: Ou, Li, et al.
Publicado: (2020)

Quantitative Analysis of α-L-Iduronidase Expression in Immunocompetent Mice Treated with the Sleeping Beauty Transposon System
por: Aronovich, Elena L., et al.
Publicado: (2013)

Case Report: Mucopolysaccharidosis Type I Treatment With α-L-Iduronidase Replacement Therapy
por: Li, Ying, et al.
Publicado: (2022)

Alpha‐L‐iduronidase deficiency: A novel mutation resulting in severe early presentation of Mucopolysaccharidosis type I and literature review of the molecular basis
por: Al Zaabi, Nuha Nasser, et al.
Publicado: (2022)

A novel p.E276K IDUA mutation decreasing α-L-iduronidase activity causes mucopolysaccharidosis type I
por: Prommajan, Korrakot, et al.
Publicado: (2011)

Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice
por: Kida, Sachiho, et al.
Publicado: (2023)

Report of 5 novel mutations of the α-L-iduronidase gene and comparison of Korean mutations in relation with those of Japan or China in patients with mucopolysaccharidosis I
por: Kwak, Min Jung, et al.
Publicado: (2016)

Brassica rapa hairy root based expression system leads to the production of highly homogenous and reproducible profiles of recombinant human alpha‐L‐iduronidase
por: Cardon, Florian, et al.
Publicado: (2018)

Comment on “report of 5 novel mutations of the α-L-iduronidase gene and comparison of Korean mutations in relation with those of Japan or China in patients with mucopolysaccharidosis I”
por: Poletto, Edina, et al.
Publicado: (2018)

Characterization and downstream mannose phosphorylation of human recombinant α-L-iduronidase produced in Arabidopsis complex glycan-deficient (cgl) seeds
por: He, Xu, et al.
Publicado: (2013)

Genotypic and bioinformatic evaluation of the alpha-l-iduronidase gene and protein in patients with mucopolysaccharidosis type I from Colombia, Ecuador and Peru
por: Pineda, Tatiana, et al.
Publicado: (2014)

Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Human Alpha-L-Iduronidase in Rhesus Macaques
por: Hordeaux, Juliette, et al.
Publicado: (2018)

Pilot study of the safety and effect of adalimumab on pain, physical function, and musculoskeletal disease in mucopolysaccharidosis types I and II
por: Polgreen, Lynda E., et al.
Publicado: (2017)

Mesenchymal Stem Cells Do Not Prevent Antibody Responses against Human α-L-Iduronidase when Used to Treat Mucopolysaccharidosis Type I
por: Martin, Priscila Keiko Matsumoto, et al.
Publicado: (2014)

Patients with Gaucher disease display systemic oxidative stress dependent on therapy status
por: Kartha, Reena V., et al.
Publicado: (2020)

Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial
por: Giugliani, Roberto, et al.
Publicado: (2018)

Identification of a novel gene fusion in ALT positive osteosarcoma
por: Mason-Osann, Emily, et al.
Publicado: (2018)

Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome
por: Okour, Malek, et al.
Publicado: (2020)

A longitudinal study of neurocognition and behavior in patients with Hurler-Scheie syndrome heterozygous for the L238Q mutation
por: Ahmed, Alia, et al.
Publicado: (2019)

A Simple and Rapid Method Based on Liquid Chromatography-Tandem Mass Spectrometry for the Measurement of α-L-Iduronidase Activity in Dried Blood Spots: An Application to Mucopolysaccharidosis I (Hurler) Screening
por: Yang, Jeong Soo, et al.
Publicado: (2015)

Development of a newborn screening tool for mucopolysaccharidosis type I based on bivariate normal limits: Using glycosaminoglycan and alpha‐L‐iduronidase determinations on dried blood spots to predict symptoms
por: Langan, Thomas J., et al.
Publicado: (2020)

Improving land-use change modeling by integrating ANN with Cellular Automata-Markov Chain model
por: Gharaibeh, Anne, et al.
Publicado: (2020)

Association of somatic burden of disease with age and neuropsychological measures in attenuated mucopolysaccharidosis types I, II and VI
por: Ahmed, Alia, et al.
Publicado: (2016)

Manuel Acuña : poeta de su siglo
por: Jarnes, Benjamín
Publicado: (1942)

Cannot write session to /tmp/vufind_sessions/sess_vrrshv9fc1l67ql5908e4lkdns